Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2016

Open Access 01-12-2016 | Primary Research

Expression of microtubule-associated protein TPX2 in human gastric carcinoma and its prognostic significance

Authors: Cuijie Shao, Changsheng Duan, Jiani Wang, Shunlian Luan, Yong Gao, Dan Jin, Deqiang Wang, Yuming Li, Lihua Xu

Published in: Cancer Cell International | Issue 1/2016

Login to get access

Abstract

Background

The molecular mechanisms underlying the development and progression of gastric carcinoma remain poorly understood. The main objective of this study was to investigate the expression level of targeting protein for Xenopus kinesin-like protein 2 (TPX2) and its clinical significance in human gastric carcinoma.

Methods

Real-time quantitative polymerase chain reaction (RT-PCR) and western blotting were used to determine the mRNA and protein levels of TPX2 in 20 paired gastric carcinoma tissues and the adjacent normal tissues, and the expression of TPX2 protein in 106 specimens of a gastric carcinoma tissue microarray was determined by immunohistochemistry. The associations of TPX2 expression with the clinicopathological features were analyzed, and the prognosis of gastric carcinoma patients was evaluated.

Results

The results showed that the expression of TPX2 mRNA was significantly higher in gastric carcinoma than in the adjacent normal tissues in 20 paired samples. Western blotting analysis revealed that TPX2 protein was differentially increased in 17 of 20 specimens from primary human gastric carcinoma tissues compared with those from adjacent non-tumor tissues. Immunohistochemical staining showed that TPX2 over-expression was significantly associated with advanced age (P = 0.001) and tumor T stage (P = 0.003). In addition, TPX2 was an independent prognostic factor for overall survival (OS) in the multivariate analysis [hazard ratio (HR) 0.001; 95 % confidence interval (CI) 2.626–7.198; P = 0.001].

Conclusions

TPX2 is up-regulated in gastric carcinoma and is associated with old age and tumor T stage. TPX2 may serve as a good prognostic indicator in patients with gastric carcinoma.
Appendix
Available only for authorised users
Literature
1.
Ferro A, Peleteiro B, Malvezzi M, Bosetti C, Bertuccio P, Levi F, Negri E, La Vecchia C, Lunet N. Worldwide trends in gastric cancer mortality (1980–2011), with predictions to 2015, and incidence by subtype. Eur J Cancer. 2014;50(7):1330–44.CrossRefPubMed
2.
Bollschweiler E, Berlth F, Baltin C, Monig S, Holscher AH. Treatment of early gastric cancer in the Western World. World J Gastroenterol. 2014;20(19):5672–8.CrossRefPubMedPubMedCentral
3.
Lan H, Zhu N, Lan Y, Jin K, Teng L. Laparoscopic gastrectomy for gastric cancer in China: an overview. Hepatogastroenterology. 2015;62(137):234–9.PubMed
4.
Zhu WG, Xua DF, Pu J, Zong CD, Li T, Tao GZ, Ji FZ, Zhou XL, Han JH, Wang CS, et al. A randomized, controlled, multicenter study comparing intensity-modulated radiotherapy plus concurrent chemotherapy with chemotherapy alone in gastric cancer patients with D2 resection. Radiother Oncol. 2012;104(3):361–6.CrossRefPubMed
5.
Hingorani M, Dixit S, Johnson M, Plested V, Alty K, Colley P, Beavis AW, Roy R, Maraveyas A. Palliative radiotherapy in the presence of well-controlled metastatic disease after initial chemotherapy may prolong survival in patients with metastatic esophageal and gastric cancer. Cancer Res Treat. 2015;47(4):706–17.CrossRefPubMedPubMedCentral
6.
Chen J, Hong D, Zhai Y, Shen P. Meta-analysis of associations between neutrophil-to-lymphocyte ratio and prognosis of gastric cancer. World J Surg Oncol. 2015;13:122.CrossRefPubMedPubMedCentral
7.
Xu X, Chang X, Li Z, Wang J, Deng P, Zhu X, Liu J, Zhang C, Chen S, Dai D. Aberrant SOX11 promoter methylation is associated with poor prognosis in gastric cancer. Cell Oncol (Dordr). 2015;38(3):183–94.CrossRef
8.
9.
Petry S, Groen AC, Ishihara K, Mitchison TJ, Vale RD. Branching microtubule nucleation in Xenopus egg extracts mediated by augmin and TPX2. Cell. 2013;152(4):768–77.CrossRefPubMedPubMedCentral
10.
Zorba A, Buosi V, Kutter S, Kern N, Pontiggia F, Cho YJ, Kern D. Molecular mechanism of Aurora A kinase autophosphorylation and its allosteric activation by TPX2. Elife. 2014;3:e02667.CrossRefPubMedPubMedCentral
11.
Neumayer G, Belzil C, Gruss OJ, Nguyen MD. TPX2: of spindle assembly, DNA damage response, and cancer. Cell Mol Life Sci. 2014;71(16):3027–47.CrossRefPubMed
12.
Peleteiro B, Castro C, Morais S, Ferro A, Lunet N. Worldwide burden of gastric cancer attributable to tobacco smoking in 2012 and predictions for 2020. Dig Dis Sci. 2015;60(8):2470–6.CrossRefPubMed
13.
Merrett ND. Multimodality treatment of potentially curative gastric cancer: geographical variations and future prospects. World J Gastroenterol. 2014;20(36):12892–9.CrossRefPubMedPubMedCentral
14.
Biondi A, Cananzi FC, Persiani R, Papa V, Degiuli M, Doglietto GB, D’Ugo D. The road to curative surgery in gastric cancer treatment: a different path in the elderly? J Am Coll Surg. 2012;215(6):858–67.CrossRefPubMed
15.
Saito M, Kiyozaki H, Takata O, Suzuki K, Rikiyama T. Treatment of stage IV gastric cancer with induction chemotherapy using S-1 and cisplatin followed by curative resection in selected patients. World J Surg Oncol. 2014;12:406.CrossRefPubMedPubMedCentral
16.
17.
Hosoda F, Arai Y, Okada N, Shimizu H, Miyamoto M, Kitagawa N, Katai H, Taniguchi H, Yanagihara K, Imoto I, et al. Integrated genomic and functional analyses reveal glyoxalase I as a novel metabolic oncogene in human gastric cancer. Oncogene. 2015;34(9):1196–206.CrossRefPubMed
18.
Mattiucci GC, Valentini C, D’Agostino GR, Augurio A, Capirci C, De Paoli A, Genovesi D, Huscher A, Iannone T, Pani G, et al. Adjuvant chemoradiotherapy in gastric cancer: a pooled analysis of the AIRO gastrointestinal group experience. Tumori. 2015;101(1):91–7.CrossRefPubMed
19.
Stiekema J, Trip AK, Jansen EP, Boot H, Cats A, Ponz OB, Verheij M, van Sandick JW. The prognostic significance of an R1 resection in gastric cancer patients treated with adjuvant chemoradiotherapy. Ann Surg Oncol. 2014;21(4):1107–14.CrossRefPubMed
20.
Zhang KC, Xi HQ, Cui JX, Shen WS, Li JY, Wei B, Chen L. Hemolysis-free plasma miR-214 as novel biomarker of gastric cancer and is correlated with distant metastasis. Am J Cancer Res. 2015;5(2):821–9.PubMedPubMedCentral
21.
Yamashita K, Kuno A, Matsuda A, Ikehata Y, Katada N, Hirabayashi J, Narimatsu H, Watanabe M. Lectin microarray technology identifies specific lectins related to lymph node metastasis of advanced gastric cancer. Gastric Cancer. 2015;19:531–42.CrossRefPubMed
22.
23.
Wang H, Wang L, Wu Z, Sun R, Jin H, Ma J, Liu L, Ling R, Yi J, Bian J, et al. Three dysregulated microRNAs in serum as novel biomarkers for gastric cancer screening. Med Oncol. 2014;31(12):298.CrossRefPubMed
24.
Wei P, Zhang N, Xu Y, Li X, Shi D, Wang Y, Li D, Cai S. TPX2 is a novel prognostic marker for the growth and metastasis of colon cancer. J Transl Med. 2013;11:313.CrossRefPubMedPubMedCentral
25.
Hsu PK, Chen HY, Yeh YC, Yen CC, Wu YC, Hsu CP, Hsu WH, Chou TY. TPX2 expression is associated with cell proliferation and patient outcome in esophageal squamous cell carcinoma. J Gastroenterol. 2014;49(8):1231–40.CrossRefPubMed
26.
Liu HC, Zhang Y, Wang XL, Qin WS, Liu YH, Zhang L, Zhu CL. Upregulation of the TPX2 gene is associated with enhanced tumor malignance of esophageal squamous cell carcinoma. Biomed Pharmacother. 2013;67(8):751–5.CrossRefPubMed
27.
28.
Aguirre-Portoles C, Bird AW, Hyman A, Canamero M, Perez de Castro I, Malumbres M. Tpx2 controls spindle integrity, genome stability, and tumor development. Cancer Res. 2012;72(6):1518–28.CrossRefPubMed
Metadata
Title
Expression of microtubule-associated protein TPX2 in human gastric carcinoma and its prognostic significance
Authors
Cuijie Shao
Changsheng Duan
Jiani Wang
Shunlian Luan
Yong Gao
Dan Jin
Deqiang Wang
Yuming Li
Lihua Xu
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2016
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-016-0357-7

Other articles of this Issue 1/2016

Cancer Cell International 1/2016 Go to the issue

Hypothesis

Comprehensive analysis of the long noncoding RNA HOXA11-AS gene interaction regulatory network in NSCLC cells

Review

Effects of the lifestyle habits in breast cancer transcriptional regulation

Primary research

Inhibition of glycolytic enzyme hexokinase II (HK2) suppresses lung tumor growth

Primary research

Schedule-dependent increased efficiency of pemetrexed-ionizing radiation combination therapy elicits a differential DNA damage response in lung cancer cells

Primary research

A humanized anti-CD26 monoclonal antibody inhibits cell growth of malignant mesothelioma via retarded G2/M cell cycle transition

Primary Research

RETRACTED ARTICLE: Mutation pattern is an influential factor on functional mutation rates in cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits